These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29701928)

  • 21. [Devotion to painting in a Parkinson's disease patient].
    Matsuda N; Kobayashi S; Ugawa Y
    Rinsho Shinkeigaku; 2018 Dec; 58(12):756-760. PubMed ID: 30487358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impulse control disorders, dopamine dysregulation syndrome and sex dysfunction in Parkinson's disease.
    Irincu L; Ivan I; Diaconu Ș; Falup-Pecurariu C
    Int Rev Neurobiol; 2022; 162():117-134. PubMed ID: 35397783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework.
    Okai D; Samuel M; Askey-Jones S; David AS; Brown RG
    Eur J Neurol; 2011 Dec; 18(12):1379-83. PubMed ID: 21615625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular imaging and neural networks in impulse control disorders in Parkinson's disease.
    Aracil-Bolaños I; Strafella AP
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S101-5. PubMed ID: 26298389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Impulsive-compulsive syndrome in Parkinson's disease].
    Nikitina AV; Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy.
    Hinnell C; Hulse N; Martin A; Samuel M
    Parkinsonism Relat Disord; 2011 May; 17(4):295-6. PubMed ID: 21300562
    [No Abstract]   [Full Text] [Related]  

  • 28. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.
    Antonini A; Chaudhuri KR; Boroojerdi B; Asgharnejad M; Bauer L; Grieger F; Weintraub D
    Eur J Neurol; 2016 Oct; 23(10):1556-65. PubMed ID: 27425586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attempted suicide under high dose dopaminergic therapy including apomorphine.
    Struhal W; Guger M; Hödl S; Ung SC; Bach M; Ransmayr G
    Wien Klin Wochenschr; 2012 Jul; 124(13-14):461-3. PubMed ID: 22797806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine Agonists and Impulse Control Disorders: A Complex Association.
    Grall-Bronnec M; Victorri-Vigneau C; Donnio Y; Leboucher J; Rousselet M; Thiabaud E; Zreika N; Derkinderen P; Challet-Bouju G
    Drug Saf; 2018 Jan; 41(1):19-75. PubMed ID: 28861870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?
    Kataoka H; Sawa N; Sugie K; Ueno S
    J Neurol Sci; 2014 Dec; 347(1-2):361-3. PubMed ID: 25454646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease.
    Smith KM; Xie SX; Weintraub D
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):864-70. PubMed ID: 26534930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced impulse control disorders in Parkinson's disease.
    Reiff J; Jost WH
    J Neurol; 2011 May; 258(Suppl 2):S323-7. PubMed ID: 21560063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased creativity associated with dopamine agonist therapy: A case report and short review of the literature.
    Thakolwiboon S; Karukote A; Julayanont P; Wilms H
    Clin Neurol Neurosurg; 2022 May; 216():107237. PubMed ID: 35395562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
    Pondal M; Marras C; Miyasaki J; Moro E; Armstrong MJ; Strafella AP; Shah BB; Fox S; Prashanth LK; Phielipp N; Lang AE
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):130-5. PubMed ID: 22933817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine 'switch'.
    Edwards MJ
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):120. PubMed ID: 22993451
    [No Abstract]   [Full Text] [Related]  

  • 37. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease.
    Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM
    Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impulse Control Disorders in Parkinson's Disease.
    Weintraub D; Mamikonyan E
    Am J Psychiatry; 2019 Jan; 176(1):5-11. PubMed ID: 30848949
    [No Abstract]   [Full Text] [Related]  

  • 39. Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Biundo R; Weis L; Abbruzzese G; Calandra-Buonaura G; Cortelli P; Jori MC; Lopiano L; Marconi R; Matinella A; Morgante F; Nicoletti A; Tamburini T; Tinazzi M; Zappia M; Vorovenci RJ; Antonini A
    Mov Disord; 2017 Nov; 32(11):1557-1565. PubMed ID: 28960475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developments in impulse control behaviours of Parkinson's disease.
    Zurowski M; O'Brien JD
    Curr Opin Neurol; 2015 Aug; 28(4):387-92. PubMed ID: 26110803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.